Clarity Pharmaceuticals (ASX:CU6) Net Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Clarity Pharmaceuticals's Net Income for the six months ended in Dec. 2023 was A$-17.20 Mil. Clarity Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Clarity Pharmaceuticals's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Clarity Pharmaceuticals's Net Margin % or its related term are showing as below:

ASX:CU6's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -157.22
* Ranked among companies with meaningful Net Margin % only.

Clarity Pharmaceuticals Net Margin % Historical Data

The historical data trend for Clarity Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Net Margin % Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Net Margin %

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Clarity Pharmaceuticals's Net Margin %

For the Biotechnology subindustry, Clarity Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarity Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Net Margin % falls into.

Clarity Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Clarity Pharmaceuticals's Net Margin for the fiscal year that ended in Jun. 2023 is calculated as

Net Margin	=	Net Income (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-24.602	/	0
	=	%

Clarity Pharmaceuticals's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-17.203	/	0
	=	%

Clarity Pharmaceuticals (ASX:CU6) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Clarity Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (ASX:CU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

CLRPF:USA

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Clarity Pharmaceuticals (ASX:CU6) Headlines

No Headlines